Glucosio S.A.L.F (Glucose Monohydrate)

Glucosio S.A.L.F is employed in clinical practice where rapid provision of carbohydrate calories is needed.

• Intravenous supplementation of glucose during surgical or diagnostic procedures to maintain energy balance.
• Temporary support for patients who cannot tolerate oral intake, such as those on fasting protocols.
• Adjunctive therapy for medically supervised correction of low blood glucose levels (hypoglycemia).
• Component of short‑term parenteral nutrition formulations providing readily available carbohydrate calories.
• Reference solution for laboratory calibration of glucose measurement devices and quality‑control testing.

When administered intravenously, Glucosio S.A.L.F may be associated with a range of observed effects, most of which are related to its glucose content.

Common

• Transient increase in blood glucose concentration.
• Mild hyperosmolarity leading to temporary thirst.
• Local irritation at the injection site.
• Nausea or mild gastrointestinal discomfort.
• Transient headache related to rapid glucose infusion.

Serious

• Severe hyperglycemia with potential osmotic diuresis.
• Electrolyte imbalance, particularly hyponatremia.
• Allergic or anaphylactic reaction to formulation components.
• Volume overload in patients with compromised cardiac function.
• Metabolic acidosis in patients with impaired lactate clearance.
• Severe hypoglycemia rebound after abrupt discontinuation.

Healthcare providers should observe specific precautions when using Glucosio S.A.L.F to ensure patient safety and optimal therapeutic outcomes.

• Verify patient’s baseline blood glucose and electrolyte status before infusion.
• Adjust infusion rate in patients with diabetes or impaired glucose tolerance.
• Use caution in individuals with renal or hepatic dysfunction due to altered glucose metabolism.
• Monitor for signs of fluid overload, especially in cardiac or pulmonary disease.
• Avoid rapid bolus administration; prefer controlled infusion to reduce osmotic shifts.
• Ensure aseptic technique to prevent catheter‑related infections.
• Document infusion details in the patient’s medical record.

Glucosio S.A.L.F can interact with other agents administered intravenously; awareness of these interactions helps prevent adverse events.

Avoid

• Concurrent rapid infusion of other hyperosmolar solutions (e.g., mannitol) that may exacerbate fluid shifts.
• Co‑administration with high‑dose insulin without appropriate glucose monitoring.
• Concurrent administration with other carbohydrate‑containing infusions, which may cause excessive hyperglycemia.

Use with caution

• Simultaneous use of diuretics that may alter electrolyte balance.
• Concurrent administration of calcium‑containing solutions, which can affect calcium‑glucose complex formation.
• Use alongside catecholamines, as they may influence glucose metabolism.
• Combination with blood products that contain citrate, potentially affecting calcium levels.
• Patients receiving glucocorticoids, as they may increase glucose production and require closer monitoring.
• Administration with other parenteral nutrition components, requiring careful monitoring of total carbohydrate load.